Abstract

(1) Background: People living with type 1 diabetes (T1D) require self-management to maintain blood glucose (BG) levels in a therapeutic range through the delivery of exogenous insulin. However, due to the various variability, uncertainty and complex glucose dynamics, optimizing the doses of insulin delivery to minimize the risk of hyperglycemia and hypoglycemia is still an open problem. (2) Methods: In this work, we propose a novel insulin bolus advisor which uses deep reinforcement learning (DRL) and continuous glucose monitoring to optimize insulin dosing at mealtime. In particular, an actor-critic model based on deep deterministic policy gradient is designed to compute mealtime insulin doses. The proposed system architecture uses a two-step learning framework, in which a population model is first obtained and then personalized by subject-specific data. Prioritized memory replay is adopted to accelerate the training process in clinical practice. To validate the algorithm, we employ a customized version of the FDA-accepted UVA/Padova T1D simulator to perform in silico trials on 10 adult subjects and 10 adolescent subjects. (3) Results: Compared to a standard bolus calculator as the baseline, the DRL insulin bolus advisor significantly improved the average percentage time in target range (70–180 mg/dL) from to () and to () in the the adult and adolescent cohorts, respectively, while reducing hypoglycemia. (4) Conclusions: The proposed algorithm has the potential to improve mealtime bolus insulin delivery in people with T1D and is a feasible candidate for future clinical validation.

Highlights

  • Diabetes is a group of metabolic disorders primarily characterized by elevated blood glucose (BG)levels, resulting from the dysfunction of insulin secretion

  • In order to evaluate the performance of the proposed algorithm, we employed a baseline method consisting of the standard bolus calculator (SBC) with fixed parameters (Equation (4)) [35]

  • We proposed a novel algorithm for meal insulin bolus dosing based on deep reinforcement learning (DRL) and continuous glucose monitoring (CGM) data

Read more

Summary

Introduction

Levels, resulting from the dysfunction of insulin secretion. Due to the destruction of pancreatic β-cells, people living with T1D suffer from the absolute deficiency of endogenous insulin production and require long-term self BG monitoring and exogenous insulin administration. To mimic the efficacy of natural insulin, there are two typical insulin replacements to reduce the abnormal increase of BG levels. One is slow-acting basal insulin, known as background insulin, constantly delivered to maintain BG levels during the periods of fasting conditions. The other is fast-acting bolus insulin that aims at compensating the BG increase after meal ingestion. Standard basal-bolus therapy is delivered through multiple daily injections (MDIs) or continuous subcutaneous insulin infusion (CSII). An MDI regimen is usually more cost-effective than CSII, Sensors 2020, 20, 5058; doi:10.3390/s20185058 www.mdpi.com/journal/sensors

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call